Nuvalent Aktie - NUVL

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

69,89

Gebot

28,00

Fragen

90,00

Volumen

930

0,00 Tagesbereich 0,00

55,535 52-Wochen-Bereich 113,51

Marktkapitalisierung

5,004B

Handelsende

70,00

Handelsbeginn

Letzte Trade

68.81

Letzter Handelszeitpunkt

14:21:55

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

552.431

Ausgegebene Aktien

71.597.920

Dividendenrendite

Kurs-Gewinn-Verhältnis

-19,22

Gewinn pro Aktie (EPS)

-3,64

Erlöse

Nettogewinn

-260,76M

Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.nuvalent.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Nuvalent Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NUVL. The last closing price for Nuvalent was US$70,00. Over the last year, Nuvalent shares have traded in a share price range of US$ 55,535 to US$ 113,51.

Nuvalent currently has 71.597.920 shares in issue. The market capitalisation of Nuvalent is US$5,01 billion. Nuvalent has a price to earnings ratio (PE ratio) of -19.22.

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum PR Newswire CAMBRIDGE, Mass., April...

Form 4 - Statement of changes in beneficial ownership of securities

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	1.64	2.40293040293	68.25	72.77	55.535	919895	63.82355078	CS
4	-7.07	-9.18659043659	76.96	79.03	55.535	638451	68.7794086	CS
12	-7.78	-10.0167374791	77.67	91.5	55.535	552431	74.29273761	CS
26	-33.58	-32.4538513579	103.47	105.13	55.535	505588	80.58890037	CS
52	4.11	6.24809972636	65.78	113.51	55.535	471827	81.76241548	CS
156	58.02	488.795282224	11.87	113.51	7.09	389937	61.61364019	CS
260	51.79	286.132596685	18.1	113.51	7.09	347583	57.75812881	CS

NUVL - Frequently Asked Questions (FAQ)

What is the current Nuvalent share price?

The current share price of Nuvalent is US$ 69,89

How many Nuvalent shares are in issue?

Nuvalent has 71.597.920 shares in issue

What is the market cap of Nuvalent?

The market capitalisation of Nuvalent is USD 5,01B

What is the 1 year trading range for Nuvalent share price?

Nuvalent has traded in the range of US$ 55,535 to US$ 113,51 during the past year

What is the PE ratio of Nuvalent?

The price to earnings ratio of Nuvalent is -19,22

What is the reporting currency for Nuvalent?

Nuvalent reports financial results in USD

What is the latest annual profit for Nuvalent?

The latest annual profit of Nuvalent is USD -260,76M

What is the registered address of Nuvalent?

The registered address for Nuvalent is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Nuvalent website address?

The website address for Nuvalent is www.nuvalent.com

Which industry sector does Nuvalent operate in?

Nuvalent operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SNYRSynergy CHC Corporation	US$ 3,86 (115,64%)	33,53M
MURAMural Oncology PLC	US$ 1,83 (77,67%)	18,29M
CSCICOSCIENS Biopharma Inc	US$ 4,64 (59,45%)	39
LEELee Enterprises Inc	US$ 13,74 (58,84%)	5
CSTECaesarstone Ltd	US$ 4,99 (58,41%)	11
RSSSResearch Solutions Inc	US$ 1,00 (-58,16%)	105
ELUTElutia Inc	US$ 0,90 (-55,22%)	261
FUSBFirst US Bancshares Inc	US$ 6,01 (-53,77%)	4
EFSIEagle Financial Services Inc	US$ 15,00 (-51,24%)	160
WVVIWillamette Valley Vineyards Inc	US$ 3,01 (-49,67%)	3
SUNESUNation Energy Inc	US$ 0,0343 (19,51%)	150,92M
DMNDamon Inc	US$ 0,00445 (3,49%)	98,91M
STSSSharps Technology Inc	US$ 0,0306 (-28,00%)	44,58M
FMTOFemto Technologies Inc	US$ 0,0341 (2,71%)	41,14M
SNYRSynergy CHC Corporation	US$ 3,8699 (116,20%)	33,53M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Nuvalent Inc (NUVL) Börsenkurse

Nuvalent Inc (NUVL)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Nuvalent Inc

NUVL Neueste Nachrichten

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Form 4 - Statement of changes in beneficial ownership of securities

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Nuvalent to Participate in Upcoming March Investor Conferences

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Form 4 - Statement of changes in beneficial ownership of securities

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Nuvalent to Participate in Upcoming March Investor Conferences

Form S-8 - Securities to be offered to employees in employee benefit plans

NUVL - Frequently Asked Questions (FAQ)

Beweger

NUVL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen